Document Detail

Rituximab Treatment for Spondyloarthritis. A Nationwide Series: Data from the AIR Registry of the French Society of Rheumatology.
MedLine Citation:
PMID:  22896028     Owner:  NLM     Status:  Publisher    
OBJECTIVE: To evaluate the efficacy and safety of rituximab (RTX) in several subsets of spondyloarthritis (SpA) using the data of the AIR (Autoimmunity and Rituximab) registry. METHODS: All patients receiving RTX for SpA, and prospectively included in the AIR registry from September 2005 to September 2010, were retrospectively analyzed. The response to treatment was evaluated by the Bath Ankylosing Spondylitis Disease Activity Index for axial disease, joint count for peripheral disease, and C-reactive protein reduction. RESULTS: Among the 595 patients included in the AIR registry, 26 patients with SpA from 13 centers were reported: ankylosing spondylitis (10), undifferentiated SpA (7), and psoriatic arthritis (9). Mean disease duration was 8.8 years (range 1-40). The extraarticular features found were psoriasis, 12 cases; uveitis, 4 cases; and Crohn's disease, 3 cases. The mean number of disease-modifying antirheumatic drugs before RTX was 2.4; previous anti-tumor necrosis factor (TNF) agents were taken in 23 cases. The mean number of RTX courses was 1.5 (range 1-5), with a total of 35.6 patient-years. Efficacy was noted in 11/23 cases: 3 out of 3 anti-TNF-naive patients and 8 out of 20 anti-TNF nonresponder patients. No predictive factors of response could be identified, particularly in diagnosis subsets or clinical presentation (axial or peripheral). CONCLUSION: In this nationwide study of several subsets of SpA, RTX had only a moderate efficacy that was more marked in patients who were anti-TNF-naive.
Daniel Wendling; Maxime Dougados; Francis Berenbaum; Olivier Brocq; Thierry Schaeverbeke; Bernard Mazieres; Christian Marcelli; Jean-Marie Leparc; Philippe Bertin; Michèle Robin; Jean Sibilia; Pierre Lafforgue; Clément Prati; Bernard Combe; Jacques-Eric Gottenberg;
Related Documents :
15965308 - Use of ziprasidone in parkinsonian patients with psychosis.
12826348 - The impact of thalamic stimulation on activities of daily living for essential tremor.
12138308 - Mitochondrial dna a4336g mutation in alzheimer's and parkinson's diseases.
5049808 - Response of patients with postencephalitic parkinsonism to levodopa.
87498 - Serum cortisol levels of multiple sclerosis patients during acth treatment.
25219678 - Radiosensitivity in patients suffering from chronic kidney disease.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-8-15
Journal Detail:
Title:  The Journal of rheumatology     Volume:  -     ISSN:  0315-162X     ISO Abbreviation:  J. Rheumatol.     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-8-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7501984     Medline TA:  J Rheumatol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
From the Department of Rheumatology, CHU de Besançon, and EA 4266, Université de Franche-Comté, Besançon; Paris-Descartes University, Paris; AP-HP, Cochin Hospital, Rheumatology B Department, Paris; Pierre et Marie Curie University, AP-HP Saint Antoine Hospital, Rheumatology, Paris, France; Princess Grace Hospital, Monaco; CHU Pellegrin, Rheumatology, Bordeaux; CHU Rangueil, Rheumatology, Toulouse; CHU, Rheumatology, Caen; AP-HP, Ambroise Paré Hospital, Rheumatology, Boulogne-Billancourt; CHU, Rheumatology, Limoges; General Hospital, Internal Medicine, Laon; CHU, Rheumatology, Strasbourg; CHU, Rheumatology, Marseille; and CHU, Rheumatology, Montpellier, France. The AIR registry was supported by an unrestricted grant from Roche France. D. Wendling, MD, PhD, Department of Rheumatology, CHU de Besançon, and EA 4266, Université de Franche-Comté; M. Dougados, MD, Paris-Descartes University, Medicine Faculty, AP-HP, Cochin Hospital, Rheumatology B Department; F. Berenbaum, MD, PhD, Paris-Pierre et Marie Curie University, AP-HP Saint Antoine Hospital, Rheumatology; O. Brocq, MD, Princess Grace Hospital; T. Schaeverbeke, MD, PhD, CHU Pellegrin, Rheumatology; B. Mazieres, CHU Rangueil, Rheumatology; C. Marcelli, MD, CHU, Rheumatology, Caen; J-M. LeParc, MD, AP-HP, Ambroise Paré Hospital, Rheumatology; P. Bertin, MD, CHU, Rheumatology, Limoges; M. Robin, MD, General Hospital, Internal Medicine, Laon; J. Sibilia, MD, PhD, CHU, Rheumatology, Strasbourg; P. Lafforgue, MD, CHU, Rheumatology, Marseille; C. Prati, MD, Department of Rheumatology, CHU de Besançon, and Université de Franche-Comté; B. Combe, MD, PhD, CHU, Rheumatology, Montpellier; J-E. Gottenberg, MD, PhD, CHU, Rheumatology, Strasbourg. Address correspondence to Dr. D. Wendling, Rheumatology, CHU, Boulevard Fleming, F-25030, Besançon, France. E-mail:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Time to Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis and Its Predictors: A...
Next Document:  Increased Organ Damage Associated with Deterioration in Volumetric Bone Density and Bone Microarchit...